Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Accumulated Expenses: 2015-2024

Historic Other Accumulated Expenses for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $421,000.

  • Syndax Pharmaceuticals' Other Accumulated Expenses rose 186.06% to $595,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $595,000, marking a year-over-year increase of 186.06%. This contributed to the annual value of $421,000 for FY2024, which is 52.59% down from last year.
  • Syndax Pharmaceuticals' Other Accumulated Expenses amounted to $421,000 in FY2024, which was down 52.59% from $888,000 recorded in FY2023.
  • Syndax Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $1.7 million for FY2021, and its period low was $421,000 during FY2024.
  • Its 3-year average for Other Accumulated Expenses is $637,667, with a median of $604,000 in 2022.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Other Accumulated Expenses skyrocketed by 222.16% in 2021 and then plummeted by 64.49% in 2022.
  • Syndax Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $528,000 in 2020, then skyrocketed by 222.16% to $1.7 million in 2021, then plummeted by 64.49% to $604,000 in 2022, then skyrocketed by 47.02% to $888,000 in 2023, then slumped by 52.59% to $421,000 in 2024.